Company news
Asymchem Laboratories (tianjin) Co., Ltd. Class A (SZSE:002821) news
Asymchem Laboratories (tianjin) Co., Ltd. Class A news releases on 6ix. Latest, Aug 4, 2026: AsymBio Secures US$184 Million Capital Injection to Support…
Press releases & updates
AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
August 4, 2026
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
March 9, 2026
AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
February 10, 2026
AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities
December 7, 2025
Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow
November 12, 2024
Building a World-Class Synthetic Biology Lab: Asymchem’s Self-Developed STAR System Empowers Protein Design
November 6, 2024
Advanced Manufacturing, Global Reach, and Streamlined Services - Asymchem Impresses at CPHI Milan 2024
October 31, 2024
Advanced Manufacturing, Global Reach, and Streamlined Services — Asymchem Impresses at CPHI Milan 2024
October 30, 2024
Asymchem Inaugurates Its First European Small Molecule Development and API Pilot Plant Manufacturing Site at Discovery Park in Sandwich, Kent, UK
August 2, 2024
Asymchem Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities
May 21, 2024